SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001493152-18-007073
Filing Date
2018-05-15
Accepted
2018-05-15 16:21:19
Documents
82
Period of Report
2018-03-31

Document Format Files

Seq Description Document Type Size
1 form10q.htm 10-Q 712330
2 ex31-1.htm EX-31.1 18627
3 ex31-2.htm EX-31.2 18976
4 ex32-1.htm EX-32.1 10730
  Complete submission text file 0001493152-18-007073.txt   4012614

Data Files

Seq Description Document Type Size
5 XBRL INSTANCE FILE immy-20180331.xml EX-101.INS 589722
6 XBRL SCHEMA FILE immy-20180331.xsd EX-101.SCH 65492
7 XBRL CALCULATION FILE immy-20180331_cal.xml EX-101.CAL 87340
8 XBRL DEFINITION FILE immy-20180331_def.xml EX-101.DEF 194888
9 XBRL LABEL FILE immy-20180331_lab.xml EX-101.LAB 399654
10 XBRL PRESENTATION FILE immy-20180331_pre.xml EX-101.PRE 299299
Mailing Address 12264 EL CAMINO REAL SUITE 350 SAN DIEGO CA 92130
Business Address 12264 EL CAMINO REAL SUITE 350 SAN DIEGO CA 92130 858-704-4042
Imprimis Pharmaceuticals, Inc. (Filer) CIK: 0001360214 (see all company filings)

IRS No.: 450567010 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-35814 | Film No.: 18836829
SIC: 2834 Pharmaceutical Preparations